Drug Profile
Chondrocyte disc regeneration therapy - Isto Biologics
Alternative Names: Allogenic juvenile chondrocytes; NuQu; NuQu® SpineLatest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator ISTO Technologies
- Developer Isto Biologics
- Class Analgesics; Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Intervertebral disc degeneration
Most Recent Events
- 27 Aug 2019 Clinical development is ongoing USA (ISTO Technologies website - August 2019)
- 01 Sep 2016 ISTO Technologies terminates a phase II trial in Intervertebral-disc-degeneration in USA (Parenteral) due to change in clinical strategy (NCT01771471)
- 09 Feb 2016 Phase-II development is ongoing in USA